Crinetics Pharmaceuticals... (CRNX)
Crinetics Pharmaceuticals Statistics
Share Statistics
Crinetics Pharmaceuticals has 92.74M shares outstanding. The number of shares has increased by 19% in one year.
| Shares Outstanding | 92.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 15.87% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 86.88M |
| Failed to Deliver (FTD) Shares | 165 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 6.25M, so 6.74% of the outstanding shares have been sold short.
| Short Interest | 6.25M |
| Short % of Shares Out | 6.74% |
| Short % of Float | 7.2% |
| Short Ratio (days to cover) | 9.68 |
Valuation Ratios
The PE ratio is -9.63 and the forward PE ratio is -15.23.
| PE Ratio | -9.63 |
| Forward PE | -15.23 |
| PS Ratio | 514.87 |
| Forward PS | 73.4 |
| PB Ratio | 3.83 |
| P/FCF Ratio | -12.08 |
| PEG Ratio | n/a |
Enterprise Valuation
Crinetics Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.06B.
| EV / Earnings | -9.62 |
| EV / Sales | 514.08 |
| EV / EBITDA | -9.31 |
| EV / EBIT | -9.27 |
| EV / FCF | -12.06 |
Financial Position
The company has a current ratio of 13.07, with a Debt / Equity ratio of 0.1.
| Current Ratio | 13.07 |
| Quick Ratio | 13.07 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 8.76 |
| Cash Flow / Debt | -3.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.4% and return on capital (ROIC) is -37.68%.
| Return on Equity (ROE) | -0.4% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -37.68% |
| Revenue Per Employee | 13.84K |
| Profits Per Employee | -739.76K |
| Employee Count | 290 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 1.38% in the last 52 weeks. The beta is 0.62, so Crinetics Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.62 |
| 52-Week Price Change | 1.38% |
| 50-Day Moving Average | 51.3 |
| 200-Day Moving Average | 50.68 |
| Relative Strength Index (RSI) | 29.82 |
| Average Volume (20 Days) | 811.45K |
Income Statement
In the last 12 months, Crinetics Pharmaceuticals had revenue of 4.01M and earned -214.53M in profits. Earnings per share was -3.69.
| Revenue | 4.01M |
| Gross Profit | 4.01M |
| Operating Income | -222.61M |
| Net Income | -214.53M |
| EBITDA | -221.51M |
| EBIT | -222.61M |
| Earnings Per Share (EPS) | -3.69 |
Balance Sheet
The company has 54.90M in cash and 51.73M in debt, giving a net cash position of 3.17M.
| Cash & Cash Equivalents | 54.90M |
| Total Debt | 51.73M |
| Net Cash | 3.17M |
| Retained Earnings | -653.70M |
| Total Assets | 937.37M |
| Working Capital | 824.02M |
Cash Flow
In the last 12 months, operating cash flow was -166.31M and capital expenditures -4.69M, giving a free cash flow of -171.00M.
| Operating Cash Flow | -166.31M |
| Capital Expenditures | -4.69M |
| Free Cash Flow | -171.00M |
| FCF Per Share | -2.94 |
Margins
Gross margin is 100%, with operating and profit margins of -5.55K% and -5.35K%.
| Gross Margin | 100% |
| Operating Margin | -5.55K% |
| Pretax Margin | -5.35K% |
| Profit Margin | -5.35K% |
| EBITDA Margin | -5.52K% |
| EBIT Margin | -5.55K% |
| FCF Margin | -4.26K% |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.65% |
| FCF Yield | -4.82% |
Analyst Forecast
The average price target for CRNX is $73, which is 91% higher than the current price. The consensus rating is "Buy".
| Price Target | $73 |
| Price Target Difference | 91% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 19.35 |
| Piotroski F-Score | 2 |